• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Delivering Better Gut Health Supplements

    Delivering Dietary Supplements that Exceed Consumer Expectations

    Green Business Network Seeks Comment on New Certification for Hemp-CBD Businesses

    Sweeteners Market Continues to Broaden with Cleaner Labels and Better Formulations

    Optimizing Gut Health: Unlocking the Gates to Well-Being
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    Study on Kemin’s DailyZz Botanical Supplement Yields Sleep Quality, Next-Day Performance Benefits

    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress

    Arla Foods Enters New Partnership to Reduce Malnutrition With Dried Papaya Snack

    Metabolaid Botanical Extract Evidenced to Reduce Blood Pressure

    BIO-CAT Microbials’ OPTI-BIOME Probiotic Strain Receives FDA 'Letter of No Objection' on GRAS Status
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    Study on Kemin’s DailyZz Botanical Supplement Yields Sleep Quality, Next-Day Performance Benefits

    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress

    Arla Foods Enters New Partnership to Reduce Malnutrition With Dried Papaya Snack

    Metabolaid Botanical Extract Evidenced to Reduce Blood Pressure

    BIO-CAT Microbials’ OPTI-BIOME Probiotic Strain Receives FDA 'Letter of No Objection' on GRAS Status
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    Study on Kemin’s DailyZz Botanical Supplement Yields Sleep Quality, Next-Day Performance Benefits

    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress

    Arla Foods Enters New Partnership to Reduce Malnutrition With Dried Papaya Snack

    Metabolaid Botanical Extract Evidenced to Reduce Blood Pressure

    BIO-CAT Microbials’ OPTI-BIOME Probiotic Strain Receives FDA 'Letter of No Objection' on GRAS Status
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Study on Kemin’s DailyZz Botanical Supplement Yields Sleep Quality, Next-Day Performance Benefits

    Metabolaid Botanical Extract Evidenced to Reduce Blood Pressure

    Study Finds People With Obesity are More Responsive To Food Marketing – Until Their Weight Drops

    Four-Week Fish Oil Regimen Showed Significant Muscular Damage Protection in Recent Study

    Review Covers Role of Vitamin K2 in the ‘Calcium Paradox’
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Chenland Nutritionals Inc.

    Nutrition21, LLC

    Xsto Solutions

    Vesta Nutra

    Verdure Sciences
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Xsto Solutions

    Gencor

    Chenland Nutritionals Inc.

    Bioenergy Life Science, Inc. (BLS)

    Nutrition21, LLC
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    The Regulatory Drumbeat Continues to Echo

    FDA’s latest actions exemplify how it views the dietary supplement industry.

    The Regulatory Drumbeat Continues to Echo
    Related CONTENT
    • Preliminary Research Suggests Osteoarthritis Benefits for Herbal Formula JointAlive
    • Schrader-Griffith Bill to Regulate CBD Re-Introduced to 117th Congress
    • Chenland Nutritionals Files NDl Notification for Joint Health Formula
    • FDA’s Steven Tave Discusses Bridging Gaps Between Regulation and Enforcement
    • Transforming Health with Nature’s Sunshine
    Todd Harrison, Venable11.01.16
    The dietary supplement industry once again finds itself in the crosshairs of U.S. regulators. In August, FDA issued its revised draft guidance document regarding New Dietary Ingredient (NDI) notifications. Subsequently, the agency has requested comments related to its tentative conclusion that vinpocetine is not a dietary ingredient—regardless of the fact that FDA, on five previous occasions, had the opportunity to raise an issue regarding its regulatory status.

    Meanwhile, the New York Attorney General (AG) reached another settlement with a large dietary supplement company regarding supply chain integrity and DNA testing (NBTY, Inc.). And the Drug Enforcement Agency (DEA) attempted to schedule a benign herb (kratom) through its emergency scheduling process. Additional developments have included recent settlements out of the State Iowa AG office and the state of California.

    What do all of these situations have in common? The constant drumbeat from regulators has been that the industry is simply not doing enough to self-regulate. This overall perception has not changed, quite frankly, since the Dietary Supplement Health and Education Act (DSHEA) was passed in October 1994; but is this all the fault of industry, or do regulators bear responsibility in this process?

    FDA’s Inaction & Ambivalence
    From my perspective, while the industry has not always done its best to comply with the requirements of DSHEA, I would argue that a large part of the blame falls on regulators—FDA in particular. The new NDI draft guidance, the NY AG’s efforts on traceability, DEA’s misstep with kratom, and even the issues surrounding claims can be directly attributable to FDA’s general ambivalence—some would say outright hostility—toward the industry. One only needs to look at the timeline to figure out that many of these issues could have been avoided if FDA would have simply taken a more active approach toward regulating the industry in 1994.

    DSHEA became effective on Oct. 14, 1994; yet during the next 22 years, FDA rarely did anything with regard to supply chain integrity and new dietary ingredients. For instance, it should not take the NY AG to enter into agreements with GNC and NBTY to make it clear that ingredient manufacturers are an integral part of ensuring supply chain integrity.

    Indeed, the issue of identity testing should not start at the finished product manufacturing stage, but rather at the ingredient manufacturing stage. Especially with botanicals, the ingredient manufacturer is in better position to conduct the initial identity testing than the finished product manufacturer. Yet, FDA made a decision to exempt ingredient manufacturers from Part 111. To this day that decision is dumbfounding to me.

    FDA continues to ignore a citizen petition by the Organic & Natural Health Association that requested the agency bring ingredient manufacturers under Part 111, even though state AGs and members of Congress have called for the same. FDA could achieve this task in short order. Instead, the NY AG is making agreements with companies to make this happen; however, these companies by themselves can’t achieve the ultimate goal, as the ingredient manufacturing industry is not of an insignificant size. 

    New Dietary Ingredients
    First, in the immortal words of Green Bay Packers Quarterback Aaron Rodgers: r-e-l-a-x, Relax. The draft guidance is just that—a draft guidance document. Moreover, it only represents FDA’s current thinking on the matter and does not have the effect of law. Forget for a moment that FDA has no ability under the law to reject a notification or to approve new dietary ingredients; as stated in my last column, the document has fundamental issues that the agency still needs to work through (September 2016, “FDA Issues Revised Draft Guidance On New Dietary Ingredients”).

    With that said, if the agency had worked with industry in 1994-1995 on developing a positive list of ingredients, as well as a policy around what would be considered a new dietary ingredient—such as a substantial change in concentration of a particular ingredient—we would not be in a situation today where we need to determine what is rightfully an “old” dietary ingredient.

    Yet, it has taken FDA more than 22 years to determine that it should compile such a list, even though the industry had compiled a list back in the mid-1990s, which FDA has refused to adopt. The agency should start with that list and request information on ingredients that are not on the list. Yet, for whatever reason, FDA is simply rejecting this approach, which is nonsensical and feeds into the general perception that the industry can’t be trusted. FDA has reinforced this perception with vinpocetine. 

    Vinpocetine’s Regulatory Status
    As everyone knows, including FDA, there were no less than five new dietary ingredient notifications regarding vinpocetine without comment from the agency. Yet, even though this ingredient is reasonably expected to be safe, in what appears to be a purely political decision sparked by Senator Claire McCaskill (D-MO), FDA decided to dig up some old press releases regarding this ingredient. 

    The industry has a reason to take issue because FDA has, at a minimum, treated the new dietary ingredient notification as a quasi-approval process—if not an outright approval process—and the industry should have been able to rely on it when making decisions about whether to incorporate a new dietary ingredient into a finished dietary supplement. This is not a situation where an ingredient supplier was relying on a Generally Recognized As Safe (GRAS) self-determination, or use in the food supply to escape the notification process. Rather, the notification was actually filed and FDA had no comment.  “No comment” does not mean FDA agrees with the notice; however, given FDA’s propensity to question these notifications, it is absurd that the agency now has a concern, stating that because it believes vinpocetine is a synthetic ingredient, subject of an investigational new drug (IND) application and substantial, public clinical trials in the U.S. prior to its introduction as a dietary ingredient. 

    Putting aside the latter point, which poses significant issues, there is simply not justification for FDA’s position on synthetic botanicals or ingredients synthesized from botanicals. Nowhere in DSHEA or its legislative history does it indicate that synthetics are not permitted. Indeed, the catch-all provision of DSHEA regarding a “dietary substance” when viewed in light of the “new” dietary ingredient notification provisions clearly contemplates that new dietary substances would be developed. Otherwise, the new dietary ingredient notification provision would rarely be used, which was not the intent of Congress. 

    Moreover, the use of the term “substance,” rather than nutrient or nutritive, clearly indicates that Congress contemplated something other than one of the specific categories delineated in the definition of a dietary supplement. In other words, “substance” contemplates synthetic ingredients that may be developed. Thus, FDA’s position on synthetic botanicals is directly at odds with Congressional intent.

    Regardless, if we are going to treat the notification process as just that—a notification process—it is difficult to penalize the agency for not understanding that an IND and substantial, public clinical trials were conducted on an ingredient. 

    Moreover, it should be required for the notifier to certify that the ingredient was not the subject of the IND and clinical trials prior to the submission of the notification. With that said, FDA is treating this requirement as an absolute bar. However, that is simply not true. More specifically, FDA has the authority to permit its use as a dietary supplement if after notice and comment the agency finds the article can be lawfully marketed as a dietary supplement. (See Federal Food, Drug, and Cosmetic Act § 201(ff)(3)(B)(ii).)  

    Of particular importance in this instance, if the drug approval had already taken place under §201(ff)(3)(A), this option would not be available. In other words, Congress recognized that there may be instances where a substance is not approved because it did not help in the treatment of a disease but would have value to overall health and well-being as a dietary substance. Accordingly, we would hope FDA understands this important distinction and use its request for comments on vinpocetine to affirm its use as a dietary ingredient; there is no question that it has never been approved as a drug in the U.S., and it has a reasonable expectation of safety based on FDA’s own review.

    As an industry, we do need to do better. However, FDA needs to step up and understand that we cannot simply hit a reset button that suddenly sends us back to October 1994. FDA should affirm vinpocetine’s use as a dietary ingredient as permitted under the FFD&C Act, abandon its view on synthetics and bring ingredient manufacturers under Part 111.


    Todd Harrison
    Venable

    Todd Harrison is partner with Venable, which is located in Washington, D.C. He advises food and drug companies on a variety of FDA and FTC matters, with an emphasis on dietary supplement, functional food, biotech, legislative, adulteration, labeling and advertising issues. He can be reached at 575 7th St. NW, Washington, D.C. 20004, Tel: 202-344-4724; E-mail: taharrison@venable.com.
    Related Searches
    • Quality & Safety
    • Dietary Supplements
    • Testing
    • Regulations
    Related Knowledge Center
    • Dietary Supplements
    • Regulations
    • Quality & Safety
    Suggested For You
    Preliminary Research Suggests Osteoarthritis Benefits for Herbal Formula JointAlive Preliminary Research Suggests Osteoarthritis Benefits for Herbal Formula JointAlive
    Schrader-Griffith Bill to Regulate CBD Re-Introduced to 117th Congress Schrader-Griffith Bill to Regulate CBD Re-Introduced to 117th Congress
    Chenland Nutritionals Files NDl Notification for Joint Health Formula  Chenland Nutritionals Files NDl Notification for Joint Health Formula
    FDA’s Steven Tave Discusses Bridging Gaps Between Regulation and Enforcement FDA’s Steven Tave Discusses Bridging Gaps Between Regulation and Enforcement
    Understanding FTC Standards for Claims Substantiation Understanding FTC Standards for Claims Substantiation
    Transforming Health with Nature’s Sunshine Transforming Health with Nature’s Sunshine
    TREHA Trehalose Available As ‘Natural Flavor’ TREHA Trehalose Available As ‘Natural Flavor’
    ConsumerLab.com Tests Popular Vitamin D Supplements ConsumerLab.com Tests Popular Vitamin D Supplements
    Gottlieb Confirmed to Lead FDA Gottlieb Confirmed to Lead FDA
    Political Disruption Presents  Opportunity for Industry Political Disruption Presents Opportunity for Industry
    Understanding GMO Labeling Legislation Understanding GMO Labeling Legislation
    How to Select the Right Partners for Your Brand How to Select the Right Partners for Your Brand
    FDA Concludes Vinpocetine Ineligible as a Dietary Ingredient FDA Concludes Vinpocetine Ineligible as a Dietary Ingredient
    FDA Issues Revised Draft Guidance On New Dietary Ingredients FDA Issues Revised Draft Guidance On New Dietary Ingredients
    NCN Webinar to Address Draft Guidance for New Dietary Ingredient Notifications
 NCN Webinar to Address Draft Guidance for New Dietary Ingredient Notifications


    Related Columns

    • Dietary Supplements | Healthcare Trends | Medical Nutrition | Regulations
      Medically Necessary Foods: Pricing & Reimbursement Considerations

      Medically Necessary Foods: Pricing & Reimbursement Considerations

      Navigating the large and growing medical foods market requires understanding key dynamics.
      By Gregory Stephens, Windrose Partners 04.08.21

    • Dietary Supplements | Regulations
      Dual Tracking of New Ingredients as Dietary Supplements and Drugs

      Dual Tracking of New Ingredients as Dietary Supplements and Drugs

      It’s possible to develop novel ingredients for both the dietary supplement and drug markets, but timing is important and there are gray areas.
      By Todd Harrison, Venable 04.08.21

    • Dietary Supplements | Probiotics & Prebiotics | Regulations | World Markets
      Probiotics & Prebiotics: The EU Ban is Shaking

      Probiotics & Prebiotics: The EU Ban is Shaking

      Some countries have not accepted the European Commission’s limitations on the term ‘probiotic’ and have implemented their own interpretations.
      By Joerg Gruenwald, analyze & realize ag 04.08.21


    • Dietary Supplements | Healthcare Trends | Immune Function | Medical Nutrition | Vitamins
      Biden COVID Response Plan Overlooks Nutrition

      Biden COVID Response Plan Overlooks Nutrition

      Our field has a unique opportunity to demonstrate the merits of our products, and the principles and philosophies behind them.
      By Erik Goldman, Holistic Primary Care 03.03.21

    • Consumer Trends | Dietary Supplements | Herbs & Botanicals | Quality & Safety
      Open Book Extracts: Innovating for Tomorrow’s Market

      Open Book Extracts: Innovating for Tomorrow’s Market

      Dave Neundorfer has a clear vision to deliver pure and consistent cannabinoids for a range of product types.
      By Sheldon Baker 03.03.21

    • Consumer Trends | Dietary Supplements | Herbs & Botanicals | Regulations
      The Evolution of Insurance for Hemp & CBD

      The Evolution of Insurance for Hemp & CBD

      Delta-8-THC is the latest wrinkle in the hemp-derived products market.
      By Chris Morey, Bolton & Company 03.03.21


    • Dietary Supplements | Healthcare Trends | Medical Nutrition | Regulations
      The Off-Label On Ramp

      The Off-Label On Ramp

      With an expanding base of clinical research supporting nutritional interventions, off label use of dietary supplements and medical foods is likely to grow.
      By Gregory Stephens, Windrose Partners, and Sheila Campbell, PhD, RD 01.19.21

    • Dietary Supplements | Healthcare Trends | Immune Function | Regulations
      ‘Follow the Science’ Often Misses the Mark with Nutrition

      ‘Follow the Science’ Often Misses the Mark with Nutrition

      The mantra too often ignores common sense approaches to improving health and quality of life.
      By Todd Harrison, Venable 01.19.21

    • Dietary Supplements | Herbs & Botanicals | Regulations | World Markets
      CBD in Europe: News from the Front

      CBD in Europe: News from the Front

      A recent decision by the Court of Justice of the European Union has restored CBD’s status, and with it, the prospects of the entire industry.
      By Joerg Gruenwald, analyze & realize ag 01.19.21


    • Delivery & Dosage Technologies | Dietary Supplements | Herbs & Botanicals | Quality & Safety
      The Advantages of Organic, Broad Spectrum Hemp

      The Advantages of Organic, Broad Spectrum Hemp

      Mike Hennesy, Wana Brands, discusses the company’s new gummies, innovation, and continuing market evolution.
      By Sheldon Baker 12.04.20

    • Dietary Supplements | Regulations
      Insurance Rates Have Been at an All-Time Low, But a Hard Market is Coming

      Insurance Rates Have Been at an All-Time Low, But a Hard Market is Coming

      Companies can be prepared by being thorough and transparent while going through insurance policy renewals.
      By Chris Morey, Bolton & Company 12.04.20

    • Dietary Supplements | Regulations
      A Business Perspective on Protecting Confidential Information: The NDA

      A Business Perspective on Protecting Confidential Information: The NDA

      Along with taking precautions in providing access to confidential information, a non-disclosure agreement can be a great way to protect your business.
      By Gregory Stephens, Windrose Partners 11.09.20


    • Dietary Supplements | Healthcare Trends | Immune Function | Regulations | Research | Vitamins
      Using All the Tools to Improve Public Health

      Using All the Tools to Improve Public Health

      Industry needs to make a stand in compelling authorities to communicate the value of nutrition and dietary supplementation.
      By Todd Harrison, Venable 11.09.20

    • Dietary Supplements | Regulations | World Markets
      Regulation Changes Calculus for Substance-Based Medical Devices

      Regulation Changes Calculus for Substance-Based Medical Devices

      The new regulation introduces more specific requirements for the technical documentation of this class of products.
      By Joerg Gruenwald, analyze & realize ag 11.09.20

    • Dietary Supplements | Healthcare Trends | Immune Function | Regulations
      Federal Regulators Slam Doctors for COVID-Related Communications

      Federal Regulators Slam Doctors for COVID-Related Communications

      Some practitioners were not selling or promoting products, they were simply suggesting certain natural substances might offer benefits in improving resilience.
      By Erik Goldman, Holistic Primary Care 10.01.20

    Trending
    • CGA-7 Green Coffee Extract By Vidya Herbs Achieves Self-Affirmed GRAS Status
    • BIO-CAT Microbials’ OPTI-BIOME Probiotic Strain Receives FDA 'Letter Of No Objection' On GRAS Status
    • Review Covers Role Of Vitamin K2 In The ‘Calcium Paradox’
    • Bunge Invests $47.5 Million In Australian Plant Proteins
    • Four-Week Fish Oil Regimen Showed Significant Muscular Damage Protection In Recent Study
    Breaking News
    • Study on Kemin’s DailyZz Botanical Supplement Yields Sleep Quality, Next-Day Performance Benefits
    • FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    • Arla Foods Enters New Partnership to Reduce Malnutrition With Dried Papaya Snack
    • Metabolaid Botanical Extract Evidenced to Reduce Blood Pressure
    • BIO-CAT Microbials’ OPTI-BIOME Probiotic Strain Receives FDA 'Letter of No Objection' on GRAS Status
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Optimizing Gut Health: Unlocking the Gates to Well-Being
    • Sweeteners Market Continues to Broaden with Cleaner Labels and Better Formulations
    • Green Business Network Seeks Comment on New Certification for Hemp-CBD Businesses
    • Delivering Dietary Supplements that Exceed Consumer Expectations
    • Delivering Better Gut Health Supplements
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Study on Kemin’s DailyZz Botanical Supplement Yields Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Arla Foods Enters New Partnership to Reduce Malnutrition With Dried Papaya Snack
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    Axalta Schedules 1Q 2021 Earnings Conference Call
    SONGWON, Chemo International Inc. Announce Distribution Partnership
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Acutus Medical Receives FDA Clearance of AcQCross
    Thermo Fisher Scientific to Acquire PPD for $17.4 Billion
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Obituary Notice: Russell “Russ” Haines
    Abenza Chooses North Carolina for New Biologics Manufacturing Site
    Catalent Adds Cryogenic Capabilities at Philadelphia Facility
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Lush Launches Recycling Scheme in UK and Ireland
    Loud Lacquer Partners with Hush Puppies
    Tula Teams Up with 5 Influencers To Launch Skin Kits
    Happi

    Latest Breaking News From Happi

    PCPC Virtual Summit Features Legal & Regulatory Conference
    Biolage Unveils ColorBalm Hair Conditioners With Hair Color Benefits
    New Synthetic Biology Coalition Formed in US
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FINAT to hold online networking, educational forum
    Epson SurePress reaches milestone
    Maxcess updates user interface for Fife guiding Sensor
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    First Quality to Discontinue Tampon Operations
    Freedonia Tracks Demand for Personal Hygiene Nonwovens
    TMC Supplies Sevinçler with D-Namic Stacker and Bagger
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Global Bone Tumor Ablation Devices Market to Top $111 Million by 2027
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login